Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Summary

This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving standard of care (SOC) antiretroviral therapy (ART). As this is an early 1st in human study and the 1st for HIV-infected individual, the safety of FT538 is confirmed prior to the addition of oral vorinostat to explore the concept of "Kick and Kill".

Timeline

Start

2024-07-15

Primary completion

2024-07-26

Completion

2024-08-21

Drugs

Indications